{"meshTagsMajor":["Point Mutation"],"meshTags":["Proto-Oncogene Proteins B-raf","Leucine","Antineoplastic Agents","Enzyme Activation","Female","Oximes","Back","Indoles","Arginine","MAP Kinase Signaling System","Melanoma","Skin Neoplasms","Sulfonamides","Point Mutation","Aged","Niacinamide","Cell Survival","Humans","Lung Neoplasms","Imidazoles","Phenylurea Compounds","Extracellular Signal-Regulated MAP Kinases"],"meshMinor":["Proto-Oncogene Proteins B-raf","Leucine","Antineoplastic Agents","Enzyme Activation","Female","Oximes","Back","Indoles","Arginine","MAP Kinase Signaling System","Melanoma","Skin Neoplasms","Sulfonamides","Aged","Niacinamide","Cell Survival","Humans","Lung Neoplasms","Imidazoles","Phenylurea Compounds","Extracellular Signal-Regulated MAP Kinases"],"genes":["BRAF","BRAF L597R"],"organisms":["9606"],"publicationTypes":["Case Reports","Journal Article","Research Support, Non-U.S. Gov\u0027t"],"title":"Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.","pubmedId":"23715574"}